Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy

Journal of Bone and Mineral Metabolism

Volumn 25, Issue 5, 2007, Pages 333-336

  Imai, Kazuhiro ^a   Yamamoto, Seizo ^a   Anamizu, Yorito ^a   Horiuchi, Toshiyuki ^a  

^a Tokyo Metropolitan Institute of Gerontology   (Japan)

Author keywords

Alendronate; Bone histomorphometry; Insufficiency fracture; Osteoporosis; Suppressed bone turnover

Indexed keywords

ALENDRONIC ACID; CALCIUM; CALCIUM LACTATE;

AGED; ARTICLE; BONE TURNOVER; CASE REPORT; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; LABORATORY TEST; MORPHOMETRICS; OSTEOPOROSIS; PELVIS FRACTURE; PRIORITY JOURNAL;

AGED; ALENDRONATE; BONE AND BONES; FEMALE; HIP FRACTURES; HUMANS; OSTEOPOROSIS; RISK FACTORS;

EID: 34548027241     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-007-0771-y     Document Type: Article

References (21)

1. JR Tucci RP Tonino RD Emkey CA Peverly U Kher AC Santora 2nd 1996 Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis Am J Med 101 488 501
2. JP Devogelaer H Broll R Correa-Rotter DC Cumming CN De Deuxchaisnes 1996 Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis Bone 18 141 150
3. DM Black SR Cummings DB Karpf JA Cauley DE Thompson MC Nevitt DC Bauer HK Genant WL Haskell R Marcus SM Ott JC Torner SA Quandt TF Reiss KE Ensrud 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348 1535 1541
4. UA Liberman SR Weiss J Broll HW Minne H Quan NH Bell J Rodriguez-Portales RW Downs Jr J Dequeker M Favus E Seeman RR Recker T Capizzi AC Santora II A Lombardi RY Shah LJ Hirsch DB Karpf 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group N Engl J Med 333 1437 1443
5. SR Cummings DM Black DE Thompson WB Applegate E Barrett-Connor TA Musliner L Palermo R Prineas SM Rubin JC Scott T Vogt R Wallace AJ Yates AZ LaCroix 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial Jama 280 2077 2082
6. HA Pols D Felsenberg DA Hanley J Stepan M Munoz-Torres TJ Wilkin G Qin-sheng AM Galich K Vandormael AJ Yates B Stych 1999 Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group Osteoporosis Int 9 461 468
7. KE Ensrud DM Black L Palermo DC Bauer E Barrett-Connor SA Quandt DE Thompson DB Karpf 1997 Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial Arch Intern Med 157 2617 2624
8. HG Bone D Hosking JP Devogelaer JR Tucci RD Emkey RP Tonino JA Rodriguez-Portales RW Downs J Gupta AC Santora UA Liberman 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women N Engl J Med 350 1189 1199
9. KE Ensrud EL Barrett-Connor A Schwartz AC Santora DC Bauer S Suryawanshi A Feldstein WL Haskell MC Hochberg JC Torner A Lombardi DM Black 2004 Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension J Bone Miner Res 19 1259 1269
10. T Mashiba T Hirano CH Turner MR Forwood CC Johnston DB Burr 2000 Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib J Bone Miner Res 15 613 620
11. T Mashiba CH Turner T Hirano MR Forwood CC Johnston DB Burr 2001 Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles Bone 28 524 531
12. SM Ott 2005 Long-term safety of bisphosphonates J Clin Endocrinol Metab 90 1897 1899
13. SM Ott 2001 Fractures after long-term alendronate therapy J Clin Endocrinol Metab 86 1835
14. CV Odvina JE Zerwekh DS Rao N Maalouf FA Gottschalk CY Pak 2005 Severely suppressed bone turnover: a potential complication of alendronate therapy J Clin Endocrinol Metab 90 1294 1301
15. AM Parfitt 2003 Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry Curr Opin Nephrol Hypertens 12 387 403
16. JD Currey 1984 Effects of differences in mineralization on the mechanical properties of bone Phil Trans R Soc London B Biol Sci 304 509 518
17. AA De Smet JR Neff 1985 Pubic and sacral insufficiency fractures: clinical course and radiologic findings Am J Roentgenol 145 601 606
18. R Schneider J Yacovone B Ghelman 1985 Unsuspected sacral fractures: detection by radionuclide bone scanning Am J Roentgenol 144 337 341
19. T Ries 1983 Detection of osteoporotic sacral fractures with radionuclides Radiology 146 783 785
20. K Takahara M Kamimura H Nakagawa S Uchiyama 2004 Changes in biochemical markers of bone in patients with insufficiency fractures J Bone Miner Metab 22 618 625
21. RR Recker DB Kimmel AM Parfitt KM Davies N Keshawartz S Hinders 1988 Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females J Bone Miner Res 3 133 144